AT-1501

DRUG6 trials

Sponsors

Anelixis Therapeutics, LLC, Eledon Pharmaceuticals

Conditions

Amyotrophic Lateral SclerosisIgA NephropathyIgANKidney Transplant RejectionPrevention of Rejection in Kidney TransplantType 1 Diabetes Mellitus

Phase 1

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

RecruitingNCT05027906

Eledon PharmaceuticalsPrevention of Rejection in Kidney Transplant

Start: 2022-02-18End: 2027-01-31Target: 48Updated: 2025-06-29

Phase 2

Multiple Doses of AT-1501-A201 in Adults With ALS

CompletedNCT04322149

Anelixis Therapeutics, LLCAmyotrophic Lateral Sclerosis

Start: 2020-10-16End: 2022-03-24Updated: 2023-06-28

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

WithdrawnNCT04711226

Anelixis Therapeutics, LLCType 1 Diabetes Mellitus

Start: 2021-02-19End: 2026-06-30Updated: 2022-08-10

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

TerminatedNCT05125068

Eledon PharmaceuticalsIgAN, IgA Nephropathy

Start: 2022-03-21End: 2023-07-31Updated: 2024-03-26

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

CompletedNCT05983770

Eledon PharmaceuticalsKidney Transplant Rejection

Start: 2023-08-30End: 2025-09-25Updated: 2026-07-22

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Enrolling by invitationNCT06126380

Eledon PharmaceuticalsKidney Transplant Rejection

Start: 2023-10-25End: 2029-12-31Target: 132Updated: 2025-12-10

Related Papers

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations

Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial

PLoS Medicine2024-10-315 citations